ABBV · AbbVie Inc.
$256.91
-0.01 (0.00%)
At close · Jul 27
Market Cap
$458.24B
Shares
1.77B
AbbVie Inc. Earnings Call Transcripts
Every quarterly earnings call for AbbVie Inc. (ABBV) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲3.3%
$14.81B
$3.95B
'22 Q3
22-10-28
▲1.6%
$15.12B
$2.47B
'22 Q4
23-02-09
▼9.7%
$12.22B
$239.00M
'23 Q1
23-04-27
▼4.9%
$13.87B
$2.02B
'23 Q2
23-07-27
▼6%
$13.93B
$1.78B
'23 Q3
23-10-27
▼5.4%
$14.30B
$822.00M
'23 Q4
24-02-02
▲0.7%
$12.31B
$1.37B
'24 Q1
24-04-26
▲4.3%
$14.46B
$1.37B
'24 Q2
24-07-25
▲3.8%
$14.46B
$1.56B
'24 Q3
24-10-30
▲5.6%
$15.10B
−$22.00M
'24 Q4
25-01-31
▲8.4%
$13.34B
$1.29B
'25 Q1
25-04-25
▲6.6%
$15.42B
$938.00M
'25 Q2
25-07-31
▲9.1%
$15.78B
$186.00M
'25 Q3
25-10-31
▲10%
$16.62B
$1.82B
'25 Q4
26-02-04
LATEST
▲12.4%
$15.00B
$695.00M
'26 Q1
26-04-29
Earnings call
FY26 · Q2
2026-07-31
AbbVie Inc. Q2 FY2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-22
AbbVie Apogee Acquisition Conference Call
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-29
AbbVie Inc. Q1 FY2026 Earnings Call
Confident tone
Skyrizi (Risankizumab) commercial performance
Rinvoq (Upadacitinib) growth and label expansion
Neuroscience portfolio (Migraine, Vraylar, Parkinson's)
Revenue
$15.00B
▲ 12.4% YoY Diluted EPS
$0.39
▼ 45.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-04
AbbVie Inc. Q4 FY2025 Earnings Call
Confident tone
Skyrizi and Rinvoq (Immunology Franchise)
Neuroscience / Psychiatry Assets
Oncology Portfolio (including EMRELIS, Epkinly)
Revenue
$16.62B
▲ 10% YoY Diluted EPS
$1.02
Gross margin
72.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-31
AbbVie Inc. Q3 FY2025 Earnings Call
Confident tone
Skyrizi and Rinvoq immunology growth
Pipeline and R&D investment
Aesthetics softness
Revenue
$15.78B
▲ 9.1% YoY Diluted EPS
$0.10
▼ 88.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
AbbVie Inc. Q2 FY2025 Earnings Call
Confident tone
Skyrizi and Rinvoq (ex-HUMIRA immunology growth)
Rinvoq pipeline expansion (GCA, alopecia areata, vitiligo)
Business development and external innovation
Revenue
$15.42B
▲ 6.6% YoY Diluted EPS
$0.52
▼ 32.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-25
AbbVie Inc. Q1 FY2025 Earnings Call
Confident tone
Ex-Humira Growth Platform (Skyrizi & Rinvoq)
R&D Pipeline & External Innovation
Aesthetics Headwinds
Revenue
$13.34B
▲ 8.4% YoY Diluted EPS
$0.72
▼ 6.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-31
AbbVie Inc. Q4 FY2024 Earnings Call
Confident tone
Aesthetics Market Challenges
Neuroscience Franchise
Oncology Pipeline
Revenue
$15.10B
▲ 5.6% YoY Diluted EPS
$-0.02
▼ 104.3% YoY Gross margin
70.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
AbbVie Inc. Q3 FY2024 Earnings Call
Confident tone
Neuroscience franchise build-out
Skyrizi commercial momentum
Rinvoq growth and label expansion
Revenue
$14.46B
▲ 3.8% YoY Diluted EPS
$0.88
▼ 12% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-25
AbbVie Inc. Q2 FY2024 Earnings Call
Confident tone
Immunology (Skyrizi/Rinvoq) growth
Humira biosimilar erosion
Aesthetics (Allergan) business
Revenue
$14.46B
▲ 4.3% YoY Diluted EPS
$0.77
▼ 32.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-26
AbbVie Inc. Q1 FY2024 Earnings Call
Confident tone
Growth Platform (ex-Humira)
Skyrizi Commercial Performance
Financial Guidance and EPS
Revenue
$12.31B
▲ 0.7% YoY Diluted EPS
$0.77
▲ 492.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-02
AbbVie Inc. Q4 FY2023 Earnings Call
Confident tone
Skyrizi and Rinvoq performance and outlook
M&A: ImmunoGen and Cerevel acquisitions
Regulatory/legislative risks (IRA, Part D redesign, GILTI)
Revenue
$14.30B
▼ 5.4% YoY Diluted EPS
$0.46
▼ 66.7% YoY Gross margin
60.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-27
AbbVie Inc. Q3 FY2023 Earnings Call
Revenue
$13.93B
▼ 6% YoY Diluted EPS
$1.00
▼ 54.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-27
AbbVie Inc. Q2 FY2023 Earnings Call
Revenue
$13.87B
▼ 4.9% YoY Diluted EPS
$1.14
▲ 123.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
AbbVie Inc. Q1 FY2023 Earnings Call
Revenue
$12.22B
▼ 9.7% YoY Diluted EPS
$0.13
▼ 94.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-09
AbbVie Inc. Q4 FY2022 Earnings Call
Revenue
$15.12B
▲ 1.6% YoY Diluted EPS
$1.38
▼ 38.9% YoY Gross margin
72.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-28
AbbVie Inc. Q3 FY2022 Earnings Call
Revenue
$14.81B
▲ 3.3% YoY Diluted EPS
$2.21
▲ 24.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-29
AbbVie Inc. Q2 FY2022 Earnings Call
Revenue
$14.58B
▲ 4.5% YoY Diluted EPS
$0.51
▲ 21.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-29
AbbVie Inc. Q1 FY2022 Earnings Call
Revenue
$13.54B
▲ 4.1% YoY Diluted EPS
$2.51
▲ 26.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-02
AbbVie Inc. Q4 FY2021 Earnings Call
Revenue
$14.89B
▲ 7.4% YoY Diluted EPS
$2.26
▲ 22500% YoY Gross margin
71.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-29
AbbVie Inc. Q3 FY2021 Earnings Call
Revenue
$14.34B
▲ 11.2% YoY Diluted EPS
$1.78
▲ 38% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-30
AbbVie Inc. Q2 FY2021 Earnings Call
Revenue
$13.96B
▲ 33.9% YoY Diluted EPS
$0.42
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-30
AbbVie Inc. Q1 FY2021 Earnings Call
Revenue
$13.01B
▲ 50.9% YoY Diluted EPS
$1.99
▼ 1.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-03
AbbVie Inc. Q4 FY2020 Earnings Call
Revenue
$13.86B
▲ 59.2% YoY Diluted EPS
$0.01
▼ 99.5% YoY Gross margin
66.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-30
AbbVie Inc. Q3 FY2020 Earnings Call
Revenue
$12.90B
▲ 52.2% YoY Diluted EPS
$1.29
▲ 2.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
AbbVie Inc. Q2 FY2020 Earnings Call
Revenue
$10.43B
▲ 26.3% YoY Diluted EPS
$-0.46
▼ 193.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-01
AbbVie Inc. Q1 FY2020 Earnings Call
Revenue
$8.62B
▲ 10.1% YoY Diluted EPS
$2.02
▲ 22.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-07
AbbVie Inc. Q4 FY2019 Earnings Call
Revenue
$8.70B
▲ 4.8% YoY Diluted EPS
$1.88
Gross margin
77.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 earnings calls
Key facts
CIK
1551152
CUSIP
00287Y109
13F (30d)
1654 filings
1600 filers
Visit website
Investor relations